{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:51Z","timestamp":1786982871596,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"JAMP Pharma Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00846-1","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:44:04Z","timestamp":1775850244000},"page":"745-765","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi\u00ae) Across Multiple Indications (EASE PAIN)"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05913817","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4075-7249","authenticated-orcid":false,"given":"Dara K.","family":"Shahrokh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald B.","family":"Vender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaggi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqqas","family":"Afif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Hillary","family":"Steinhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"6","key":"846_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234705","volume":"15","author":"JA Sacrist\u00e1n","year":"2020","unstructured":"Sacrist\u00e1n JA, Dilla T, D\u00edaz-Cerezo S, Gab\u00e1s-Rivera C, Aceituno S, Liz\u00e1n L. Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature. PLoS ONE. 2020;15(6):e0234705. https:\/\/doi.org\/10.1371\/journal.pone.0234705.","journal-title":"PLoS ONE"},{"key":"846_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102193","volume":"64","author":"GBD 2019 IMID Collaborators","year":"2023","unstructured":"GBD 2019 IMID Collaborators. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019. EClinicalMedicine. 2023;64:102193. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102193.","journal-title":"EClinicalMedicine"},{"issue":"978","key":"846_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","volume":"83","author":"A Kuek","year":"2007","unstructured":"Kuek A, Hazleman BL, \u00d6st\u00f6r AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251. https:\/\/doi.org\/10.1136\/pgmj.2006.052688.","journal-title":"Postgrad Med J"},{"issue":"10055","key":"846_CR4","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(16)30173-8.","journal-title":"Lancet"},{"issue":"4","key":"846_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","volume":"7","author":"A St Clair-Jones","year":"2020","unstructured":"St Clair-Jones A, Prignano F, Goncalves J, Paul M, Sewerin P. Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatol Ther. 2020;7(4):741\u201357. https:\/\/doi.org\/10.1007\/s40744-020-00245-0.","journal-title":"Rheumatol Ther"},{"key":"846_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","volume":"101","author":"H Mitoma","year":"2018","unstructured":"Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-\u03b1 agents \u2013 comparison among therapeutic TNF-\u03b1 antagonists. Cytokine. 2018;101:56\u201363. https:\/\/doi.org\/10.1016\/j.cyto.2016.08.014.","journal-title":"Cytokine"},{"key":"846_CR7","unstructured":"HUMIRA\u00ae - PRODUCT MONOGRAPH. In: Corporation A, editor.; 2021."},{"key":"846_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40744-020-00256-x","volume":"8","author":"M Bergman","year":"2021","unstructured":"Bergman M, Patel P, Chen N, et al. Evaluation of adherence and persistence differences between adalimumab citrate-free and citrate formulations for patients with immune-mediated diseases in the United States. Rheumatol Ther. 2021;8:109\u201318. https:\/\/doi.org\/10.1007\/s40744-020-00256-x.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"846_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40744-016-0041-3","volume":"3","author":"P Nash","year":"2016","unstructured":"Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40\u00a0mg\/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3(2):257\u201370. https:\/\/doi.org\/10.1007\/s40744-016-0041-3.","journal-title":"Rheumatol Ther"},{"key":"846_CR10","volume-title":"EQ-5D-5L user guide","author":"EuroQol Research Foundation","year":"2019","unstructured":"EuroQol Research Foundation. EQ-5D-5L user guide. Rotterdam: EuroQol Research Foundation; 2019."},{"issue":"4","key":"846_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaf139","volume":"9","author":"K J\u00e4ppinen","year":"2025","unstructured":"J\u00e4ppinen K, Muilu P, Autio R, et al. Physician global assessment in rheumatoid arthritis. Rheumatol Adv Pract. 2025;9(4):rkaf139. https:\/\/doi.org\/10.1093\/rap\/rkaf139.","journal-title":"Rheumatol Adv Pract"},{"issue":"11","key":"846_CR12","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00296-016-3546-8","volume":"36","author":"E Nikiphorou","year":"2016","unstructured":"Nikiphorou E, Radner H, Chatzidionysiou K, et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Rheumatol Int. 2016;36(11):1489\u201399. https:\/\/doi.org\/10.1007\/s00296-016-3546-8.","journal-title":"Rheumatol Int"},{"key":"846_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2024-004379","author":"A Misa-Garcia","year":"2025","unstructured":"Misa-Garcia A, Ferro-Rodr\u00edguez S, Haro-Mart\u00edn L, Cavero-Redondo I. Influence of volume and citrate on perceived pain in patients treated with adalimumab. Eur J Hosp Pharm. 2025. https:\/\/doi.org\/10.1136\/ejhpharm-2024-004379.","journal-title":"Eur J Hosp Pharm"},{"issue":"21","key":"846_CR14","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1523\/JNEUROSCI.2087-20.2021","volume":"41","author":"YL Yang","year":"2021","unstructured":"Yang YL, Lai TW. Citric acid in drug formulations causes pain by potentiating acid-sensing ion channel 1. J Neurosci. 2021;41(21):4596\u2013606. https:\/\/doi.org\/10.1523\/JNEUROSCI.2087-20.2021.","journal-title":"J Neurosci"},{"issue":"11","key":"846_CR15","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/j.1553-2712.1998.tb02667.x","volume":"5","author":"AM Kelly","year":"1998","unstructured":"Kelly AM. Does the clinically significant difference in visual analog scale pain scores vary with gender, age, or cause of pain? Acad Emerg Med. 1998;5(11):1086\u201390. https:\/\/doi.org\/10.1111\/j.1553-2712.1998.tb02667.x.","journal-title":"Acad Emerg Med"},{"issue":"1","key":"846_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1067\/mem.2001.111517","volume":"37","author":"CV Powell","year":"2001","unstructured":"Powell CV, Kelly AM, Williams A. Determining the minimum clinically significant difference in visual analog pain score for children. Ann Emerg Med. 2001;37(1):28\u201331. https:\/\/doi.org\/10.1067\/mem.2001.111517.","journal-title":"Ann Emerg Med"},{"key":"846_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251332025","volume":"18","author":"G D\u2019Abbundo","year":"2025","unstructured":"D\u2019Abbundo G, Nachury M, Wartski A, et al. Switch acceptance and persistence of Adalimumab biosimilars in IBD patients: a prospective observational study. Ther Adv Gastroenterol. 2025;18:17562848251332025. https:\/\/doi.org\/10.1177\/17562848251332025.","journal-title":"Ther Adv Gastroenterol"},{"issue":"7","key":"846_CR18","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00228-024-03676-8","volume":"80","author":"EH San","year":"2024","unstructured":"San EH, Egberts A, van Dijck-van Boetzelaer CWT, West RL, Vasbinder EC. High refill-adherence to adalimumab is associated with low disease activity in patients with inflammatory bowel disease. Eur J Clin Pharmacol. 2024;80(7):1089\u201396. https:\/\/doi.org\/10.1007\/s00228-024-03676-8.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00846-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00846-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00846-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:46:40Z","timestamp":1779526000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00846-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["846"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00846-1","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dara K. Shahrokh is an employee at JAMP Pharma. Ronald B. vender receives grants\/research support, speakers bureau, honoraria from AbbVie, Alumis, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Dermavant, Dermira, DICE, Eli Lilly, Galderma, Incyte, JAMP Pharma, Janssen, LEO, Meiji Seika Pharma, Nimbus Therapeutics, Novartis, Pfizer, Sanofi-Aventis, Sandoz, Sun Pharma, Takeda, UCB Pharma, Zai Lab Co. Ltd. Jaggi Rao receives grants\/research support, speaker honoraria, and consulting fees from AbbVie, Actelion, Allergan, Amgen, Aspen, Bausch Health, Cipher, Clarion, Cutera, Cynosure, Eli Lilly, Galderma, Jan Marini, Janssen, L\u2019Oreal, LEO Pharma, Lumenis, MD Medical, Medexus, Merz, Miravo, Novartis, Organon, Pfizer, Sandoz, Sanofi, Sciton, Seaford, Servier, Sun Pharma, Thermi, Vivier. Charles W. Lynde receives grants\/research support, speaker honoraria, and consulting fees from AbbVie, Acelyrin, Akros, Altius, Amgen, Apogee, Aralez, Arcutis, Avillion, Bausch Health, Bayer, BioJAMP, Bioderma, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celldex, Celltrion, CeraVe, Cipher, Concert, DICE, Dermavant, Dermira, Devonian, Eli Lilly, Evelo, Fresenius Kabi, GSK, Galderma, InCyte, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, L\u2019Oreal, LEO Pharma, La Roche Posay, MedX, Medexus, Merck, Moonlake, Naos, Nektar, Nimbus, Novartis, Organon, Oruka, P&G, PediaPharm, Pfizer, Regeneron, Roche, Sandoz, Sanofi, Sanofi Genzyme, Searchlight Pharma, Sentrex, Skinceuticals, Sun Pharma, Takeda, UCB, Volo Health, Vyne. Waqqas Afif is supported by the following companies: AbbVie, Amgen, Avir, BMS, Celltrion, Eli Lilly, Janssen, Innomar, Pfizer, Sandoz, Sanofi, Takeda. A. Hillary Steinhart is supported by the following companies: AbbVie, Amgen, Arena, BMS, Celltrion, Celgene, Ferring, Fresenius Kabi, Genentech, Gilead, JAMP Pharma, Janssen, Merck, Morphic Therapeutic, NKS Pharmacy, Pfizer, Pharmascience, Roche, Sanofi, Sandoz, Takeda. Neeraj Narula has received honoraria from Janssen, AbbVie, Takeda, Pfizer, Sandoz, Novartis, Iterative Health, Innomar Strategies, Fresenius Kabi, Amgen, Organon, Eli Lilly, and Ferring. Louis Bessette is supported by the following companies: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Eli Lilly, Novartis, Sanofi, Teva, Fresenius Kabi, Sandoz, JAMP Pharma, Organon, a consultant for: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Celgene, Eli Lilly, Novartis, Sanofi, Gilead, Teva, Fresenius Kabi, Sandoz, Organon, Sobi; and research: Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Celgene, Sanofi, Lilly, Novartis, Gilead, AstraZeneca, JAMP Pharma. Evelyn Sutton is on the steering committee of this study and is and ad board member for AbbVie and past president of CRA. Carter Thorne is supported by the following companies: AbbVie, Accord, Amgen, AstraZeneca, BI, Biogen, BMS, Celgene, CaRE-Biodam, Centocor, Genzyme, GSK, Hospira, JAMP, Janssen, Lilly, Medexus\/Medac, Merck, Nordic, Novartis, Organon, Pfizer, Roche, Sandoz, Sanofi, Takeda, TcLand, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and the appropriate regulatory requirements in Canada. The protocol, its amendments, and informed consent documentation were reviewed and approved by the institutional review board(s) or independent ethics committee(s) at each study site. The study protocol (Protocol v2.0) was approved on March\u00a03, 2023, by the independent Ethics Committee of Advarra (372 Hollandview Trail, Suite 300, Aurora, ON, L4G 0A5, Canada (Reference number Pro00069327)) and all study sites accepted the Advarra ethics committee approval. All patients provided written informed consent prior to entry to the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}